Innovate UK

StimOxyGen is a biotechnology company focused on developing innovative, pH-responsive nanoparticles. These nanoparticles are designed to generate oxygen in hypoxic (low oxygen) tumors, enhancing the effectiveness of cancer treatments like radiotherapy and chemotherapy. The company's core technology involves a nanoparticle formulation that dissolves in the low pH environment of tumors, transiently producing oxygen and thereby maximizing the therapeutic effects of radiotherapy.

LinkGevity is a biotechnology company specializing in drug discovery, with a focus on longevity and age-related diseases. It operates an AI-powered platform designed to expedite the development of life-saving medications. By combining AI and pharmaceutical expertise, the company analyzes extensive datasets to predict and identify promising drug candidates, aiming to extend healthy lifespan and bring innovative treatments to market more swiftly.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Lentitek is a cell and gene therapy company developing gene therapies and gene-modified cell therapies to broaden access to cures. It focuses on increasing the production yields of lentiviral vectors through its platform, using a novel promoter and proprietary production methods. The approach aims to deliver substantially higher yields, potentially reducing manufacturing costs and improving scalability for healthcare providers delivering gene therapies.

Mestag Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases through its unique fibroblast technology. The company leverages emerging insights into the role of activated fibroblast populations in disease progression to create therapeutics that disrupt fibroblast-mediated effects on immune cells. By targeting these mechanisms, Mestag aims to enhance treatment options and improve outcomes for patients suffering from rare and life-threatening conditions.

Naitive is a population health company that develops AI-enabled clinical pathways. It uses artificial intelligence, clinical data, digital interventions, and scalable computational capabilities to enhance chronic disease case-finding, treatment, and care coordination, aiming to transform patient care and reduce associated costs.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

BoobyBiome operates a microbiome research platform and develops probiotic supplements for infants with compromised microbiomes, including premature babies, to promote gut health and immune development by closely mirroring the beneficial bacteria found in breast milk.

Awen Oncology is a pre-clinical stage pharmaceutical company focused on developing novel cancer therapies. It specializes in targeting 'developmentally-silent oncogenic drivers', which are genes that contribute to cancer growth but are not typically targeted by existing treatments. The company's approach combines expertise in cell and molecular biology with advanced structural biology and in-silico drug screening to rapidly and efficiently identify and develop effective cancer treatments.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

BiVictriX Therapeutics Ltd. is a drug discovery and development company based in Alderley Edge, United Kingdom, focused on creating bispecific antibody drug conjugates to address unmet medical needs in blood cancer. Established in 2016, the company leverages its proprietary Bi-Cygni technology to develop innovative therapies for various types of cancers, including Acute Myeloid Leukaemia. BiVictriX specializes in oncology and haematological malignancies, offering a range of services that encompass biotherapeutics, immunotherapy, antibody research, and drug development. The company aims to advance its pharmaceutical products through rigorous development processes to improve treatment outcomes for patients with serious medical conditions.

Nuclera specializes in accelerating drug discovery by providing a protein prototyping system. Its eProtein Discovery™ platform enables scientists to rapidly produce and test proteins for research purposes.

Founded in London in 2016, LIfT BioSciences develops a proprietary platform for allogeneic innate immuno-cell therapy. Its Neutrophil Only Leukocyte Infusion Therapy (N-LIfT®) enables scalable production of Immunomodulatory Alpha Neutrophils (IMAN®s) from induced pluripotent stem cells (iPSCs), offering potential mono or combo therapies.

Monument Therapeutics is a biotechnology company focused on developing drugs for treating serious diseases of the central nervous system. Its innovative approach employs proprietary digital biomarkers to reduce patient heterogeneity, enabling more targeted neuroscience drug development in areas with unmet medical needs.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

Presymptom Health is a medical technology company dedicated to advancing healthcare through the development of pre-symptomatic diagnostic tests and clinical decision support algorithms. The company focuses on creating innovative blood tests designed to detect illnesses at an early stage, particularly aiming to predict the onset of sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health seeks to improve critical care outcomes and enhance patient management, ultimately contributing to better survival rates and healthcare efficiency.

IXICO plc, established in 1995 and headquartered in London, specializes in providing data analytics services to the global biopharmaceutical industry. The company focuses on the collection, analysis, management, and reporting of data generated during clinical studies, with a particular emphasis on neurological diseases. IXICO's key technologies include Assessa, a digital platform for clinical decision support, and TrialTracker, a comprehensive imaging service workflow management system. The company's end-to-end imaging services are primarily applied in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases. IXICO's services are utilized to select patients for clinical trials, assess drug safety and efficacy, and for post-marketing surveillance. The company works with pharmaceutical companies, biotech firms, academia, and medical charities worldwide.

Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.

Aelius Biotech specializes in developing models of the mucosal surfaces within the human body. Currently, they focus on simulating the gastrointestinal tract and airways, with ongoing efforts to model the eye and cervico-vaginal tract.

SökerData is a biotechnology company that specializes in research and data analysis solutions focused on disease-related datasets. The company has developed a data visualization platform designed to analyze biomarkers in clinical outcomes across various demographics. This platform provides researchers with essential features and tools for interpreting large datasets, facilitating early drug discovery. By enabling researchers to better understand the impact of biomarkers on different populations, SökerData supports informed decision-making and enhances the comprehension of disease outcomes in diverse demographic groups.

PulmoBioMed is a company focused on providing innovative solutions for clinicians and researchers through non-invasive sampling of fluids. The firm has developed a passive fluid aerosol sampler designed to capture exhaled breath condensate and aerosol samples. This product effectively segregates exhaled and environmental particles by size, addressing critical challenges such as sample contamination and loss. PulmoBioMed's technology aims to generate highly reproducible data with precise digital molecular analysis, facilitating the study of biological agents and supporting metabolomic profiling. Through its advancements, the company seeks to enhance research capabilities and improve patient outcomes in the field of respiratory health.

Lucida Medical develops artificial intelligence–based healthcare technology to aid clinicians in the detection and diagnosis of cancer. Its platform analyzes imaging data from MRI and integrates imaging and multi-omics biomarkers and reporting tools to support cancer screening and diagnosis, with the aim of making detection more accurate, accessible, and faster while reducing costs. The company’s first product, Pi, is designed to assist in diagnosing prostate cancer using multiparametric or diffusion MRI and is a CE marked medical device.

Cyted specializes in digital diagnostic infrastructure, utilizing AI and innovative biomarkers for early disease detection. Its mission is to transform diagnostic methods, aiming for a world where diseases are prevented rather than treated.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Physiomics Plc is a consulting firm based in Oxford, United Kingdom, specializing in services for pharmaceutical companies in the realms of quantitative pharmacology and computational biology. Established in 2001, the company utilizes its proprietary Virtual Tumour predictive software to offer modeling, simulation, and data analysis services, primarily focused on oncology research and development. By combining systems biology with advanced mathematical techniques, Physiomics aims to optimize dosing and scheduling of oncology drugs during pre-clinical and clinical trials, enhancing the efficacy of drug combinations and streamlining the overall drug development process. The company's operations extend across the United Kingdom, the European Union, Switzerland, and the United States, with a commitment to advancing personalized medicine through innovative technology.

Founded in 2012, Stablepharma specializes in developing processes for vaccine stabilization. Its flagship product, Stablevax, enables precise dosage pre-loading into syringes at manufacture, eliminating wastage. The company's technology platform converts existing vaccines and diagnostics into thermostable products, addressing global cold chain challenges.

AstronauTx focuses on restoring healthy function of astrocytes, a type of brain cell crucial for neuronal health and blood-brain barrier integrity. Its primary goal is to develop treatments targeting astrocyte dysfunction in dementias like Alzheimer's disease.

ZiO Health is a biotechnology company that develops pocket-sized devices featuring proprietary biosensor technology and machine learning algorithms. These devices enable real-time laboratory testing at the point-of-care, enhancing patient care by combining immediate results with individual patient profiles.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research. By combining expertise from matrix biologists, cancer scientists, toxicologists, and biomaterial engineers, Peptimatrix offers a more reproducible, reliable, and ethical alternative to traditional cell culture methods. The company's mission is to provide researchers with a better way to model development and disease.

Kalium Health Ltd is a medical technology company based in Cambridge, United Kingdom, that specializes in designing and manufacturing innovative tests for blood potassium concentration. Founded in 2018 and previously known as Kalium Diagnostics Ltd, the company focuses on patient-centric approaches to manage kidney disease, which significantly impacts healthcare costs. Kalium Health is developing a user-friendly finger-prick blood test that allows patients to monitor their potassium levels conveniently and affordably, addressing a critical risk associated with kidney disease. This technology aims to provide real-time, clinically actionable health insights into cardiorenal diseases, thereby transforming the standard of care for millions of patients. With a clear regulatory pathway and a targeted go-to-market strategy, Kalium Health is positioned to make a significant impact in the field of kidney care.

genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade'​ business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.

Autolomous develops pragmatic software solutions for cell and gene therapy manufacturers. Its platform, autoloMATE®, offers end-to-end solutions including resource scheduling, electronic batch records management, insights reporting, review, and release activities. The platform aligns with US FDA, EU EMA & UK MHRA guidance and is certified ISO 27001:2013 (information security), ISO 9001:2015 (quality management), and ISO 14001:2015 (environmental management).

The Cell and Gene Therapy Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. With over 120 experts and state-of-the-art laboratories at Guy's Hospital in London, CGT Catapult is building a £55m large-scale manufacturing centre to accelerate market access for these therapies.

Neu Health develops a smartphone-based clinical platform for personalized care in Parkinson's disease and dementia. The platform uses AI to monitor symptoms, optimize condition management, reduce clinician burden, and improve patient outcomes.

Lindus Health is a clinical research organization that specializes in managing end-to-end clinical trials for healthcare and biotechnology companies. The company offers services such as ethics and IRB submissions, trial monitoring, data management, biostatistics, regulatory affairs, and payor relations. Lindus Health employs an in-house team of clinicians and researchers to accelerate the clinical trial process using its proprietary software platform, Curebase OS, which automates workflows and reduces manual inefficiencies. The company also leverages real-world patient data for precise participant recruitment and smarter trial design, aiming to make clinical trials faster and more cost-effective while improving patient treatment outcomes.

QV Bioelectronics develops an innovative electric field therapy implant, GRACE, designed to extend the lives of brain tumor patients while maintaining their quality of life. This first-of-its-kind device targets glioblastoma, a cancer with poor outcomes, by slowing tumor growth and sparing healthy tissue.

GenoMe Diagnostics is a biotechnology company focused on developing innovative blood tests for early cancer detection. Its flagship product, OvaME, aims to improve the current standard of CA125 blood tests.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

Fallouh Healthcare specializes in the development and manufacturing of medical devices and AI-based software for cardiac surgery. Their products aim to enhance patient safety and streamline surgical workflows. Key offerings include systems for monitoring and protecting the heart during surgery, and AI-driven tools to detect and prevent complications like tamponade.

Brainstem is a DePIN to collect and utilise wearable health data. Our mission is to revolutionize healthcare and improve lives through remote screening, ongoing monitoring, digital treatment alternatives, and tools to share data with practitioners, researchers, and others. We are committed to building a network of users who are willing to share their data and embracing collaboration with smart minds to speed innovation. With our vision of being a 24/7 virtual health assistant specializing in sleep, mental, cardio, and neuro health, we are at the forefront of digital health.

52 North Health develops an AI-powered medical device for determining neutropenic sepsis risk in chemotherapy patients. Its portable finger-prick blood test measures neutrophil count and C-Reactive Protein (CRP) levels at home, enabling early detection and improved management of this fatal side effect.

The Medicines Discovery Catapult is the centre of national expertise for the discovery of medicines.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

ProtonDx is a diagnostic company delivering molecular testing through a point-of-care platform that enables rapid and sensitive detection of multiple infectious pathogens from patient samples. Its microchip-based technology combines molecular biology and machine learning and can be rapidly deployed in hospitals to assist clinicians in diagnosing infectious diseases, managing infected patients, and providing real-time insights for outbreak tracking.

Aten Therapeutics specializes in developing novel therapeutic antibodies targeting fundamental control pathways associated with major diseases. Their experienced management team aims to extend and improve patients' lives by creating powerful new treatments.

BoobyBiome operates a microbiome research platform and develops probiotic supplements for infants with compromised microbiomes, including premature babies, to promote gut health and immune development by closely mirroring the beneficial bacteria found in breast milk.

BoobyBiome operates a microbiome research platform and develops probiotic supplements for infants with compromised microbiomes, including premature babies, to promote gut health and immune development by closely mirroring the beneficial bacteria found in breast milk.

Awakn Life Sciences is a clinical-stage biotechnology company dedicated to developing and delivering innovative psychedelic medicine aimed at treating addiction, with a primary focus on Alcohol Use Disorder (AUD). The company comprises a multidisciplinary team of chemists, scientists, psychiatrists, and psychologists who are working to create the next generation of psychedelic drugs and therapies, as well as the technologies that enable their use. Recognizing the inadequacies of current treatment options for AUD, Awakn aims to provide breakthrough therapeutics for individuals suffering from addiction, addressing a significant medical need both in the United States and internationally.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Founded in 2018 by industry veterans in neuroscience drug discovery, NRG Therapeutics is a biotechnology company dedicated to developing therapeutic approaches that restore mitochondrial function. Their primary focus is slowing or halting the progression of neurodegenerative diseases like Parkinson's and Alzheimer's through innovative drug discovery.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

BoobyBiome operates a microbiome research platform and develops probiotic supplements for infants with compromised microbiomes, including premature babies, to promote gut health and immune development by closely mirroring the beneficial bacteria found in breast milk.

Medwise.ai operates a customizable search platform that uses natural language processing and artificial intelligence technologies to provide clinical decision support for doctors. Its real-world data offers insights to various healthcare stakeholders, enabling doctors to organize medical knowledge and enhance patient care outcomes.

GenoMe Diagnostics is a biotechnology company focused on developing innovative blood tests for early cancer detection. Its flagship product, OvaME, aims to improve the current standard of CA125 blood tests.

Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.

Oxford Heartbeat develops medical device software to improve surgical planning and execution. The platform allows surgeons to visualize what is happening inside blood vessels and surrounding tissues and bones, offering unprecedented visibility for minimally invasive, keyhole procedures. Through predictive computations, big data and AI, it enables rehearsals of procedures and helps choose the best surgical scenario for each patient in advance. Better preparation aims to reduce complication rates and related costs while delivering improved patient care.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

CryoLogyx is an early-stage biotechnology company that develops cryopreservation technology to produce frozen, ready-to-use cells for drug discovery, diagnostics, and cell therapies. Its approach protects cells during freezing using cryoprotectants, enabling viable cells to be stored and transported in formats tailored to researchers' needs. The technology aims to transform how cells are stored and delivered, ensuring cells and cell therapies are available in the desired format whenever needed.

Founded in 2015 and based in Cambridge, UK, Camallergy is a biopharmaceutical company focused on developing innovative treatments for food allergies. Its lead product is an oral immunotherapy designed to provide significant protection against peanut allergy within just three months.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating the physiological functions of human organs. CN Bio's offerings include microphysiological systems and consumables, used by various industries to analyze novel compounds, assess toxicity and safety, and support research scientists in investigating biological processes. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharma and biotech firms. CN Bio, part of Hong Kong-based CN Innovations Holdings Limited, works closely with academic experts and is backed by prestigious grants, aiming to accelerate the development of transformative therapies worldwide.

IgniteData is a company focused on transforming clinical trials through innovative technology solutions. Its flagship product, Archer, is a cloud-based virtual research assistant that facilitates secure transmission of clinical data from electronic health records to electronic data capture systems. By automating patient data processes, IgniteData aims to enhance the efficiency of clinical research, enabling researchers to collect trial data more swiftly. This approach not only accelerates the development of crucial therapies but also improves the quality of studies while reducing the workload for research teams. Ultimately, IgniteData is dedicated to streamlining key clinical research processes to ensure that important medical advancements reach patients more quickly.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

NovaBiotics Ltd. is a clinical-stage biotechnology company focused on designing and developing first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. Its lead product, Novexatin (NP213), is a topical treatment for fungal nail infections, affecting over 10% of the global population.

BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

Ablatus Therapeutics Limited is a medical device company based in Norwich, United Kingdom, focused on developing and commercializing innovative tissue ablation technology for the treatment of challenging and often inoperable solid cancer tumors. Founded in 2015, the company has created a proprietary Bimodal Electric Tissue Ablation system that utilizes radiofrequency (RF) energy to generate localized heating and effectively destroy target tissues. This advanced approach provides clinicians with new options for treating tumors, aiming to improve patient outcomes in oncology care.

Reflection Therapeutics is developing cell therapy technology against neuroinflammation across the board.

Albus Health is a startup spun out from the University of Oxford. It has developed an intelligent nocturnal monitoring platform that offers personalized, passive, contactless, and objective monitoring of various symptoms and environmental metrics at home. The platform has been commercialized and is currently used by leading pharmaceutical companies to monitor nocturnal symptoms in clinical trials, with the potential to predict respiratory emergencies.

QV Bioelectronics develops an innovative electric field therapy implant, GRACE, designed to extend the lives of brain tumor patients while maintaining their quality of life. This first-of-its-kind device targets glioblastoma, a cancer with poor outcomes, by slowing tumor growth and sparing healthy tissue.

Medwise.ai operates a customizable search platform that uses natural language processing and artificial intelligence technologies to provide clinical decision support for doctors. Its real-world data offers insights to various healthcare stakeholders, enabling doctors to organize medical knowledge and enhance patient care outcomes.

ONKO is a provider of unified cancer care. ONKO combines digital technology with the support of healthcare professionals to provide patients with personalised expertise from cancer dietitians, physiotherapists, specialist nurses and psychologists.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, established in 2011 in Stirling, United Kingdom. The company addresses the growing global demand for niche sterile manufacturing by providing filling and finishing services tailored to the needs of biotech and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis distinguishes itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. With a commitment to maintaining regulatory compliance, Symbiosis supports its clients in navigating the complexities of drug product development and supply.

Cyted specializes in digital diagnostic infrastructure, utilizing AI and innovative biomarkers for early disease detection. Its mission is to transform diagnostic methods, aiming for a world where diseases are prevented rather than treated.

Lunac Therapeutics develops advanced oral anticoagulant medicines designed to prevent and treat life-threatening thrombotic events. The treatments seek to balance efficacy with safety by minimizing bleeding risk while preserving therapeutic effect, enabling clinicians to manage high-risk patients with safer dosing strategies.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions and processes, particularly in the areas of infections and oncology. Its flagship product, True Point-of-Care, utilizes advanced molecular methods, including polymerase chain reaction (PCR), to deliver rapid and accurate results. This capability allows clinics and medical professionals to detect infections swiftly and make informed treatment decisions in a decentralized healthcare setting, ultimately improving patient outcomes.

BrainWaveBank, established in 2015, is a UK-based brain health research company. It specializes in developing data-centric solutions to track and understand cognitive health. The company's flagship product, also named BrainWaveBank, is a wearable EEG headset that measures brain activity while users engage in mobile games, enabling daily tracking of cognitive health at home. This data is securely stored and analyzed, creating neurocognitive profiles for individuals and populations, and aiding clinical professionals in advancing brain health research and treatments. The company has offices in Belfast, Northern Ireland, and Dublin, Ireland.

Px HealthCare is a company focused on enhancing patient experiences to achieve better oncology outcomes. It has developed the OWise platform, which consists of evidence-based mobile and web applications tailored for individuals living with breast and prostate cancer. OWise promotes value-based cancer care by providing personalized digital tools that allow patients to share health data in real time with their healthcare teams. The platform addresses the financial and individual burdens of cancer, aiming to improve patients' well-being and clinical outcomes while also reducing healthcare costs. The OWise app has been recognized for its effectiveness, with high recommendations from both patients and clinicians. Px HealthCare leverages advanced data analytics to analyze anonymized, real-world patient-reported outcome data, generating insights that can enhance treatment effectiveness and cost-efficiency. Overall, OWise serves as a key patient-driven support platform, integrating improved patient experience, clinical outcomes, and economic viability in cancer care.

Healum develops AI-powered collaborative software that empowers individuals with long-term conditions to monitor and understand their physical and mental health. The platform uses data-driven insights and evidence-backed interventions to support patients and facilitate personalized care.

Albus Health is a startup spun out from the University of Oxford. It has developed an intelligent nocturnal monitoring platform that offers personalized, passive, contactless, and objective monitoring of various symptoms and environmental metrics at home. The platform has been commercialized and is currently used by leading pharmaceutical companies to monitor nocturnal symptoms in clinical trials, with the potential to predict respiratory emergencies.

The Cell and Gene Therapy Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. With over 120 experts and state-of-the-art laboratories at Guy's Hospital in London, CGT Catapult is building a £55m large-scale manufacturing centre to accelerate market access for these therapies.

Freeline Therapeutics is a clinical-stage biotechnology company specializing in systemic adeno-associated virus (AAV)-based gene therapies. Its pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A, all in various stages of clinical trials.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, established in 2011 in Stirling, United Kingdom. The company addresses the growing global demand for niche sterile manufacturing by providing filling and finishing services tailored to the needs of biotech and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis distinguishes itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. With a commitment to maintaining regulatory compliance, Symbiosis supports its clients in navigating the complexities of drug product development and supply.

Nanna Therapeutics Limited, established in 2012 and headquartered in Cambridge, UK, is a biotechnology company focused on developing drugs for age-related diseases such as mitochondrial, neurodegenerative, cardiovascular/metabolic, joint/tissue diseases, and cancer. As of April 2020, the company operates as a subsidiary of Astellas Pharma Europe Ltd. Nanna Therapeutics employs a unique approach by targeting fundamental cellular processes to create innovative treatments for these conditions, with a particular emphasis on mitochondria, the energy source in every cell. The company's proprietary drug discovery platform, TIME (Totally Integrated Medicines Engine), combines advanced technologies like microfluidics and artificial intelligence to accelerate drug development and disrupt traditional methods of creating new medicines.

Concentric Health is a company focused on transforming health decision-making through its innovative e-consent application. The application enhances efficiency by addressing backlog issues and minimizing medico-legal risks through the use of trusted content. It aims to simplify complex processes for both patients and clinicians, fostering shared decision-making that is informed by patient outcomes. By providing a secure and auditable platform, Concentric Health improves the overall experience for users, ultimately leading to better health outcomes.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

A UK pharmaceutical development company, AKL Research & Development Ltd (AKLRD) is committed to transforming patient’s lives through innovative solutions that meet unmet needs.AKLRD is developing novel therapeutics for inflammatory diseases with a high unmet need, including osteoarthritis, Alzheimer’s, rheumatoid arthritis & scleroderma, a rare connective tissue disease.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

MediSieve Ltd. is a London-based medical device company specializing in Magnetic Blood Filtration (MBF) technology aimed at treating blood-borne diseases. Founded in 2014, the company has developed a system that utilizes a magnetic filter to physically remove infected blood cells from a patient's bloodstream. The process involves circulating blood through an external loop where targeted magnetic particles are infused, binding to disease-relevant targets. This filtered blood then passes through a magnetic filter that captures the particles and bound targets, allowing the unaffected blood to return to the patient without the particles entering their body. MediSieve's innovative approach is applicable to various conditions, including malaria, leukaemia, sepsis, and other blood-borne diseases, enhancing the efficacy and safety of existing therapies. The company operates out of the Imperial Incubator in White City, London, where it conducts product development and validation in its dedicated laboratory facilities.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

RoslinCT is a UK-based Contract Development and Manufacturing Organisation (CDMO) that specializes in cell and gene therapy. The company offers a range of services tailored for organizations developing cell-based therapeutic products. Its expertise encompasses tissue procurement, cryopreservation studies, pre-clinical studies, and analytical development. By providing these services, RoslinCT enables its clients to create compliant, sustainable, and cost-effective therapies, supporting advancements in the field of regenerative medicine.

Medherant is a clinical-stage company focused on transdermal drug delivery for pain and central nervous system conditions. Its TEPI Patch uses an adhesive technology designed to enable higher drug loading, controlled release, and compatibility with a wide range of drug types, addressing limitations of conventional patches and reducing issues seen with creams and gels. The platform emphasizes water resistance and efficient drug delivery to improve patient comfort and therapeutic effectiveness. Medherant originated from academic work at the University of Warwick led by Professor David Haddleton and was founded in 2014 in Coventry, United Kingdom, with a goal to commercialise transdermal delivery platforms that broaden the applicability of transdermal administration for diverse medicines.